Literature DB >> 1735998

Lung transplantation. Analysis of thirty-six consecutive procedures performed over a twelve-month period. The Washington University Lung Transplant Group.

D A Haydock1, E P Trulock, L R Kaiser, N A Ettinger, A N Triantifillou, L L Ochoa, M K Pasque, S R Knight, J D Cooper.   

Abstract

A consecutive series of 36 lung transplant procedures in 35 patients, performed over a 12-month period, has been reviewed. There were 14 men and 21 women undergoing 23 single, 12 bilateral, and one en bloc double lung transplant. There were one hospital death and three late deaths in the series, giving a hospital survival rate of 97.2% and a 1-year actuarial survival figure of 91.7%. Airway complications occurred in six patients (17.2%), one of whom died. Cytomegalovirus infection was demonstrated in 18 patients (51%), but no deaths have resulted. The most common cardiac complication was an atrial tachyarrhythmia (nine patients, 25.7%) and three patients had a cardiac arrest, but all were successfully resuscitated. Twelve patients required a further 25 surgical procedures after transplantation; however, renal and hematologic complications were uncommon. The prevalence and management of the other associated complications is discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1735998

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  2 in total

1.  Graft damage after a single lung transplantation for pulmonary hypertension in a rat model.

Authors:  S Yamamoto; K Kawahara; T Takahashi; S Akamine; T Tagawa; A Nakamura; M Muraoka; S Ide; N Sasaki; H Shingu; T Nagayasu; N Yamasaki; M Tomita
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

2.  Inhaled nitric oxide ameliorates postoperative acute graft dysfunction after living-donor lobar lung transplantation.

Authors:  T Yoshikawa; H Date; M Yamashita; I Nagahiro; M Aoe; N Shimizu
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2000-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.